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 Introduction: A Genetic Perspective 
of the Host-Pathogen Interaction
The determinism of human infectious diseases is 
still vastly misconstrued. Because exposure to a 
pathogen is requisite for infection and disease to 
occur, infectious diseases are often regarded as 
textbook examples of purely environmental dis-
eases. However, a characteristic feature of many 
human infectious diseases is the interindividual 
variability in the development and progression of 
clinical disease. While a significant contribution 
might be credited to virulence traits of the infec-
tious agent, recent evidence has highlighted the 
dominant role of heritable factors in defining sus-
ceptibility to infection [1–6]. Twin studies have 
played a significant part in unraveling host 
genetic factors involved in susceptibility to infec-
tious diseases, although the relative contribution 
of heredity and environment to infection in twins 
remains disputed [7]. Nonetheless, a ground-
breaking study from the late 1980s reported that 
adopted children had a prominently increased 
risk of death from infectious diseases if at least 
one of their biological parents had died prema-
turely from the same infection [8]. Mouse studies 
have also widely illustrated the importance of 
host genetic- driven effects, by showing dispari-
ties between inbred strains concerning pathogen 
loads, cytokine responses, and outcomes follow-
ing infection [9]. Thus, there is considerable evi-
dence supporting the contribution of host genetics 
to infectious disease; a well-known example is 
the protective role of the sickle cell trait against 
the severe forms of malaria caused by Plasmodium 
falciparum [10].
Our current understanding of the genetic sus-
ceptibility to human infectious diseases is derived 
from the study of individuals with rare mono-
genic defects underlying susceptibility to a nar-
row range of pathogens and from population- based 
studies to identify common polymorphisms asso-
ciated with disease. Such landmark discoveries 
have established that predisposition to infection 
segregates in either a Mendelian (monogenic) or 
a polygenic pattern of inheritance. By implicat-
ing these genetic variants in the immune response 
to selected pathogens, these reports have pro-
vided crucial insights into the genetic control of 
antimicrobial host defenses in humans. Extension 
of these genetic approaches to the dissection of 
the associated molecular and cellular mecha-
nisms may further unravel the genetic architec-
ture of susceptibility to infectious diseases and 
support future studies evaluating host-pathogen 
genetic interactions and potentially driving clini-
cal translation. In particular, the analysis of the 
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transcriptional landscape of the host-pathogen 
interaction under conditions of specific immune 
deficiency may contribute to the disclosure of the 
permissive conditions underlying the emergence 
of different infectious diseases. In this chapter, 
we focus on genetic variation in pattern recogni-
tion receptors (PRRs) and its role in susceptibil-
ity to infectious diseases in patients with primary 
and acquired immunodeficiencies. Also dis-
cussed is the impact of genetic variation in these 
receptors on the activation of antimicrobial 
immune responses and how these processes can 
be exploited in personalized medical interven-
tions based on individual host genetic profiles.
 Genetic Principles and Approaches 
for Identifying Susceptibility Genes
Perhaps the most compelling evidence that host 
genetics indeed determines the development of 
infectious disease arises from primary immuno-
deficiencies, first described in the late 1940s and 
early 1950s [1]. Primary immunodeficiencies 
usually present with infections due to common or 
opportunistic pathogens, resulting from a clear-
cut deficit in a single gene. Such immune dys-
function is usually limited to a very small number 
of individuals or families, but the identification of 
the underlying genetic defects is very informative 
on immune defense mechanisms. On the other 
hand, susceptibility to infections in the general 
population can be influenced by polymorphisms 
across multiple genes, with the specific contribu-
tion to the phenotype being typically more diffi-
cult to establish.
The current interest in the role of rare, large- 
effect variants as predisposing factors to 
infectious diseases has prompted the description 
of an increasing number of single-gene defects 
underlying phenotypes associated with a certain 
pathogen selectivity. The identification of 
mutations in individual immune-related genes 
influencing susceptibility to a narrow range of 
different pathogens has led to the evolving 
concept of pathogen-selective immunodeficiency 
[11]. It should be stressed that although these 
immunodeficiency states are widely considered 
to be discriminating, the specificity of pathogen 
susceptibility is not always absolute. Nevertheless, 
the range of pathogen diversity is typically much 
narrower in humans than that observed in the 
corresponding mouse knockout models. One 
difference is that human studies involve naturally 
acquired infection while mouse models generally 
involve administration of pathogens, often at 
high inocula to induce disease.
Early studies of genetic susceptibility to infec-
tious diseases resorted to genome-wide linkage 
analyses and candidate gene approaches and 
identified only a restricted number of strongly 
associated loci that have been independently vali-
dated. Linkage approaches have been employed 
successfully in the study of monogenic diseases 
and were successively applied in attempts to 
define the susceptibility loci underlying common 
diseases. The most commonly used design 
involved the study of affected sibling pairs and 
had some degree of success in identifying loci 
linked to some infectious diseases, in particular 
leprosy [12]. However, a major drawback of link-
age analyses lies in the difficulty in recruiting 
numerous multicase families in which two sib-
lings are affected and by the lack of adequate 
study power [3].
Candidate gene studies comprise the genotyp-
ing of common polymorphisms in biologically 
plausible genes and pathways, typically in unre-
lated case and control individuals. The degree of 
replication between candidate gene studies is 
often poor, most likely due to small sample sizes 
limiting the study power, unrecognized popula-
tion stratification, failure to correct for multiple 
testing during statistical analysis, and missing or 
inaccurate clinical information. Additional 
causes for lack of replication may include differ-
ences across studies in the phenotypic definition 
of cases (e.g., a significant bias might be intro-
duced by the use of different diagnostic proce-
dures) and controls, unidentified variation in 
gene-environment interactions, and actual genetic 
heterogeneity between populations [13]. The 
candidate gene approach is further hampered by 
its reliance on existing and possibly inaccurate 
biological hypotheses to select genes for study. 
Despite these limitations, candidate gene studies 
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have disclosed a number of robust, independently 
replicated associations with infectious diseases.
 Pattern Recognition Receptors 
and Innate Immunity
In 1992, Charles Janeway, Jr., advanced the field 
of innate immunity toward new horizons with his 
concept of selective recognition of conserved 
microbial structures by germline-encoded PRRs 
[14]. Indeed, it is nowadays well established that 
the first step in the development of an innate 
immune response implicates pathogen 
recognition by PRRs in an acute and conserved 
fashion [15]. Although there are substantial 
differences in the ways in which the multiple 
innate cell populations recognize specific 
pathogens, the overall framework is similar and 
involves the binding of conserved pathogen- 
associated molecular patterns (PAMPs) such as 
microbial cell wall constituents, nucleic acids, or 
metabolic products by PRRs. There are five 
major classes of receptors: Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), 
nucleotide-binding oligomerization domain 
(NOD) leucine-rich repeat containing receptors 
(NLRs), retinoic acid-inducible gene I protein 
(RIG-I) helicase receptors, and absent in 
melanoma 2 (AIM2)-like receptors (ALRs) [6]. 
Generally, by inducing the secretion of 
proinflammatory cytokines and chemokines, 
PRRs not only mediate downstream intracellular 
events related to pathogen clearance but also 
participate in complex and disparate processes of 
immunomodulation and activation of adaptive 
immunity through the coordination of T cell and 
B cell responses [16]. Pathogen recognition by 
the innate immune system is further supported by 
the opsonic activity of soluble PRRs, including 
collectins, ficolins, pentraxins, and complement 
components, which facilitate the interaction with 
phagocytes. On the other hand, PRRs are also 
able to respond to products released from 
damaged host cells during infection and other 
causes of injury (e.g., trauma and ischemia 
reperfusion), including nucleic acids and alarmin 
proteins, collectively known as danger-associated 
molecular patterns.
The role of TLRs in antimicrobial defense was 
first proposed in 1996 by Lemaitre and colleagues, 
following the observation that fruit flies lacking 
the hematocyte receptor Toll – which indirectly 
recognizes pathogens through the cytokine-like 
protein Spätzle  – were highly susceptible to 
infection with fungi and Gram-negative bacteria 
[17]. This study was followed shortly by the 
discovery of TLRs expressed on cells of the 
mammalian immune system, and since then, 13 
TLRs have been discovered. The extracellular 
domains of these receptors contain leucine-rich 
repeats that recognize PAMPs from all major 
classes of pathogens, whereas the amino acid 
sequence of the cytoplasmic domain is highly 
homologous to the sequences in the interleukin 
(IL)-1 and IL-18 receptors [18]. Ligand 
recognition by TLRs and intracellular signaling 
transduction by adaptor molecules that contain 
Toll-IL-1R (TIR) domains activate kinase 
cascades and promote the translocation of 
transcription factors to the nucleus, where they 
induce gene expression and downstream 
production of cytokines [15, 19] (Fig. 6.1).
The large family of CLRs includes members 
such as dectin-1, dectin-2, macrophage mannose 
receptor, dendritic cell-specific intercellular 
adhesion molecule 3-grabbing non-integrin 
(DC-SIGN), macrophage inducible C-type lectin 
(Mincle), macrophage C-type lectin (MCL), and 
dectin-2. These receptors have carbohydrate 
recognition domains and bind microbial 
polysaccharides commonly present in fungi and 
bacteria [20]. Dectin-1 was the first CLR to be 
identified and is currently the best described non- 
TLR receptor able to instruct activation of 
adaptive immunity. Following recognition of 
β-1,3-glucans, dectin-1 triggers different 
intracellular signaling pathways that, 
synergistically and through cross-regulatory 
mechanisms, regulate and fine-tune nuclear 
factor (NF)-κB activation and cytokine gene 
expression [21] (Fig. 6.2).
In addition to the mainly membrane-bound 
TLRs and CLRs, there are cytoplasmic 
receptors  – NLRs and the DNA-sensing RIG-I 
helicase receptors  – that are activated by 
pathogens when they invade a cell. NLRs 
recognize the peptidoglycans of the bacterial cell 
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wall and can activate inflammasomes, multimeric 
protein complexes that convert inactive pro-IL-1β 
and pro-IL-18 into bioactive cytokines [22]. The 
NLR family members NOD-containing receptors 
1 (NOD1) and NOD2 recognize muramyl peptide 
moieties of the peptidoglycans of Gram-negative 
and Gram-positive bacteria, respectively [23, 24]. 
The RIG-I helicase receptors are known to 
recognize mainly viral nucleic acids and to 
activate inflammasome formation [25]. 
Fig. 6.1 Genetic defects affecting Toll-like receptor sig-
naling and their role in susceptibility to infection. Toll- 
like receptors (TLRs) are present on the cell surface and in 
endosomes, where they detect pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide 
(LPS), lipoprotein, flagellin, CpG DNA, and double- 
stranded RNA.  Upon stimulation, TLRs activate two 
disparate pathways that involve myeloid differentiation 
primary response 88 (MyD88) and/or Toll-interleukin 
(IL)-1 receptor (TIR) domain-containing adapter-inducing 
interferon (IFN)-β (TRIF). Crosstalk between TLR 
signaling cascades underlies the activation of different 
cellular processes, including the transcription of 
proinflammatory cytokines and chemokines and type I 
IFN. Major genetic variation in TLR signaling pathways 
implicated in susceptibility to infection is indicated in 
purple (rare), red (common), or green (evidence of both 
rare and common variation). TIRAP Toll-interleukin-1 
receptor (TIR) domain-containing adaptor protein, TRAM 
TRIF-related adaptor molecule, IRAK IL-1 receptor- 
associated kinase, TRAF tumor necrosis factor receptor- 
associated factor, UNC93B1 unc-93 homologue B1, TAK1 
transforming growth factor-β-activated kinase 1, NF-κB 
nuclear factor-κB, NEMO NF-κB essential modulator, 
IKK inhibitor of NF-κB kinase, IκB inhibitor of NF-κB, 
IRF IFN regulatory factor, TBK1 TANK-binding kinase 1, 
PI3K phosphoinositide 3-kinase, dsRNA double-stranded 
RNA
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Ultimately, the coordinated regulation of the 
immune response will depend not only on the 
relative degree of stimulation of the individual 
receptors but also on the level of receptor 
cooperation and cellular localization. For 
example, synergy between TLRs and NOD2 is 
crucial for the activation of host defense against 
mycobacteria and staphylococci [26], and 
crosstalk between TLRs and CLRs is needed for 
optimal antifungal responses [27].
Fig. 6.2 Genetic defects affecting C-type lectin receptor 
signaling and their role in susceptibility to infection. The 
family of C-type lectin receptors (CLRs) recognizes 
microbial polysaccharides commonly present in fungi and 
bacteria. Cord factor is a commonly used term to refer to 
trehalose dimycolate, a glycolipid molecule found in the 
cell wall of M. tuberculosis and similar species. Upon 
stimulation, CLRs activate intracellular signaling 
pathways that, synergistically and through cross- 
regulatory mechanisms, regulate and fine-tune nuclear 
factor (NF)-κB activation and cytokine gene expression. 
Major genetic variation in CLR signaling pathways 
implicated in susceptibility to infection is indicated in 
purple (rare) or red (common). FCγR Fcγ receptor, MCL 
macrophage C-type lectin, SYK spleen tyrosine kinase, 
PKCδ protein kinase C-δ, MyD88 myeloid differentiation 
primary response 88, TIRAP Toll-interleukin-1 receptor 
(TIR) domain-containing adaptor protein, IRAK IL-1 
receptor-associated kinase, TRAF tumor necrosis factor 
receptor-associated factor, CARD9 caspase recruitment 
domain-containing protein 9, BCL10 B cell CLL/
lymphoma 10, MALT1 mucosa-associated lymphoid 
tissue lymphoma translocation protein 1, NF-κB nuclear 
factor-κB, NEMO NF-κB essential modulator, TAK1 
transforming growth factor-β-activated kinase 1, IKK 
inhibitor of NF-κB kinase
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 Genetic Defects in Pattern 
Recognition Receptors 
and Susceptibility to Infection
Genetic variants in the genes encoding PRRs can 
affect susceptibility to many infectious diseases. 
Importantly, genetic defects in these receptors or 
the downstream signaling pathways can cause 
immunodeficiency phenotypes rendering patients 
extremely susceptible to severe, life-threatening 
infections. We know of genetic defects across the 
different classes of PRRs, although in some cases 
(e.g., the NLR family) these have yet to be linked 
with susceptibility to infection. An overview of 
the genetic variants affecting PRRs reported in 
association with susceptibility to specific 
infectious diseases is presented in Table 6.1.
 Genetic Variation in Toll-Like 
Receptor Signaling
Soon after the initial description of TLRs, genetic 
variability in these molecules was proposed to 
underlie differences in susceptibility to infectious 
and inflammatory diseases [28]. The first genetic 
variation to be described was polymorphisms in 
TLR4, specifically two amino acid changes 
reported to decrease the interaction of the receptor 
with lipopolysaccharide [29] and to increase 
susceptibility to Gram-negative bacterial sepsis 
[30]. During the subsequent decade and up until 
now, a multitude of studies described genetic 
variation in practically all TLRs (Fig. 6.1).
Myeloid differentiation primary response 88 
(MyD88) is an adaptor molecule that transduces 
signals from TLRs (with the exception of TLR3 
and the IL-1 and IL-18 receptors) [31]. The sig-
naling involves a cascade of protein kinases 
which include the serine-threonine IL-1R- 
associated kinase 4 (IRAK4) [19]. The activation 
of the MyD88 and IRAK4 pathways has been 
deemed essential for the immune response to 
pyogenic bacteria based on the study of patients 
with rare mutations in these genes that resulted in 
invasive disease by Streptococcus pneumoniae 
and, to a lesser extent, by Staphylococcus aureus, 
Pseudomonas aeruginosa, or Salmonella species 
[32, 33]. Several hypomorphic mutations have 
been identified in MYD88 and IRAK4 genes; two 
of them leading to MyD88 deficiency affecting 
amino acids in key positions for the interaction of 
the adaptor with IRAK4 [34]. Despite the mani-
fest susceptibility to pyogenic bacteria, children 
with MyD88 and IRAK4 deficiency are typically 
resistant to other bacteria, mycobacteria, viruses, 
and fungi, and classically, their immunodefi-
ciency improves with age, with less frequent and 
less severe forms of infection [35]. This may sug-
gest that the development of protective T cell- or 
B cell-mediated immune responses after infancy 
compensates for the defective inflammatory reac-
tion in the absence of proper TLR signaling [36].
Mutations in genes from the NF-κB pathway 
that interrupt multiple innate and adaptive 
pathways that signal to NF-κB, including TLR- 
mediated signaling, have also been identified 
[37–40]. In particular, hypomorphic mutations in 
NF-κB essential modulator (NEMO), which 
encodes the I-κB kinase regulatory subunit IKKγ, 
and IκBα inhibitor of NF-κB (IKBA) have been 
reported to underlie typically severe infections by 
a broad range of pathogens, including 
encapsulated bacteria, atypical mycobacteria, 
fungi, and viruses, and are also associated with 
ectodermal dysplasia [37–40].
In addition to the RIG-I helicase receptors, 
TLR3, TLR7, TLR8, and TLR9 bind to different 
microbial nucleic acids [15, 19]. Genetic defects 
in TLR3 [41] or proteins involved in the TLR3 
pathway such as unc-93 homologue B1 
(UNC93B1) [42] and TIR-domain-containing 
adapter-inducing interferon (IFN)-β (TRIF) [43] 
or tumor necrosis factor (TNF) receptor- 
associated factor 3 (TRAF3) [44] have been 
identified as rare causes of isolated susceptibility 
to recurrent, life-threatening encephalitis caused 
by herpes simplex virus-1 (HSV-1) in otherwise 
healthy children displaying normal resistance to 
other forms of HSV disease and indeed to other 
viruses. Herpes simplex encephalitis (HSE) has 
been linked to defects in the release of type I IFN, 
and importantly, blocking TLR3-dependent 
production of interferons in vitro enhanced viral 
replication leading to cell death, effects that were 
abrogated by recombinant IFN-β [41]. 
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Accordingly, children with HSE have been found 
to carry different heterozygous mutations in 
TRAF family member-associated NF-κB 
activator (TANK)-binding kinase 1 (TBK1), a 
kinase at the crossroads of multiple IFN-inducing 
signaling pathways [45]. Similar to TLR3 
deficiency, fibroblasts from these patients 
displayed enhanced viral replication, whereas 
responses to TLR3-independent viruses were 
instead preserved. These findings were 
substantiated by the identification of a deficiency 
in the signal transducer and activator of 
transcription 1 (STAT1) protein, a signaling 
molecule in the type I IFN pathway, that resulted 
in the production of insufficient levels of type I 
IFN and susceptibility to HSE [46, 47].
A novel genetic etiology of HSE due to hetero-
zygous loss-of-function in the IFN regulatory fac-
tor 3 (IRF3) gene – activated by several TLRs that 
bind viruses [48] – was also identified, providing 
the first description of a defect in an IFN-
regulating transcription factor that confers 
increased susceptibility to viral infection of the 
human central nervous system [49]. Genetic sus-
ceptibility to other viruses, particularly influenza, 
among otherwise healthy children was also 
Table 6.1 Monogenic and polygenic defects in pattern recognition receptors and susceptibility to infectious diseases
PRR deficiency Presumed defect(s) Reported infection(s) Frequency
TLR signaling
MyD88 TLR signaling Pyogenic bacteria Very rare
(Except TLR3)
IRAK4 TLR signaling Pyogenic bacteria Very rare
(Except TLR3)
NEMO TLR signaling Pyogenic bacteria Very rare
IKBA TLR signaling Pyogenic bacteria Very rare
TLR3 dsRNA recognition HSV Very rare
dsRNA recognition Aspergillus Common
UNC93B1 dsRNA recognition HSV Very rare
TRIF TLR3 signaling HSV Very rare
TRAF3 TLR3 signaling HSV Very rare
TBK1 TLR3 signaling HSV Very rare
IRF3 TLR3 signaling HSV Very rare
IRF7 TLR7 and/or RIG-I signaling Influenza virus Very rare
TLR1 Lipopeptide recognition Gram (+) bacteria, Candida Common
TLR4 LPS recognition Gram (−) bacteria, Aspergillus Common
TLR5 Flagellin recognition Legionella Common
TIRAP TLR2 and TLR4 signaling Mycobacterium, gram (−) bacteria Common
CLR signaling
Dectin-1 β-Glucan recognition Candida, Trichophyton, Aspergillus Common
CARD9 CLR signaling Trichophyton, Exophiala Very rare
MCL MCF recognition Mycobacterium Common
Soluble PRRs
MBL Opsonization Neisseria, Streptococcus Common
PTX3 Opsonization and fungicidal activity Aspergillus Common
PLG Opsonization Aspergillus Common
PRR pattern recognition receptor, TLR Toll-like receptor, CLR C-type lectin receptor, MyD88 myeloid differentiation 
primary response 88, IRAK4 interleukin-1 receptor (IL-1R)-associated kinase 4, NEMO nuclear factor-κB (NF-κB) 
essential modulator, IKBA IκBα inhibitor of NF-κB, UNC93B1:unc-93 homologue B1, TRIF Toll-IL-1R (TIR) domain- 
containing adapter-inducing interferon β (IFNβ), TRAF3 tumor necrosis factor receptor-associated factor 3, TBK1 
TRAF family member-associated NF-κB activator-binding kinase 1, IRF IFN regulatory factor, TIRAP TIR domain- 
containing adaptor protein, CARD9 caspase recruitment domain-containing protein 9, MCL macrophage C-type lectin, 
MBL mannose-binding lectin, PTX3 long pentraxin 3, PLG plasminogen, dsRNA double-stranded RNA, RIG-I retinoic 
acid-inducible gene I protein, MCF mycobacterial cord factor, HSV herpes simplex virus
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reported to result from compound heterozygous 
null mutations in IRF7 [50]. In response to influ-
enza virus, cells from these patients produced 
very little type I and III IFN while failing to con-
trol viral replication, suggesting that IRF7-
dependent amplification of type I and III IFN is 
essentially required for protection against primary 
infection by influenza virus in humans.
Although the complete deficiencies in the 
TLR pathways have a large effect size, they are 
generally rare events (with the remarkable 
exception of TLR5 deficiency, discussed below) 
on the scale of an entire population. The genes 
encoding TLRs are however prominently poly-
morphic and encode many variant amino acid 
sites. Before the advent of genome-wide associa-
tion studies (GWAS), polymorphisms in TLRs 
were considered outstanding, biologically plau-
sible candidates for involvement in enhanced 
susceptibility to multiple infectious diseases 
[28]. Common polymorphisms in all TLRs have 
been described and a wealth of studies have 
reported their association with infection suscep-
tibility. Excellent literature has already described 
those association studies in detail; therefore, we 
will focus mainly on discussing the most rele-
vant studies evaluating TLR polymorphisms and 
their functional implications in the immunodefi-
cient host.
As mentioned above, a TLR4 haplotype con-
sisting of the D299G and T399I substitutions has 
been shown to be associated with an increased risk 
of sepsis [30] and is suggested to result in defec-
tive responses to lipopolysaccharide [29]. 
However, several other studies have failed to repli-
cate these data at both genetic and functional lev-
els [51], raising issues related to small sample 
sizes, population stratification, or the definition of 
case status. Interestingly, an enhanced production 
of TNF upon TLR4 stimulation has been demon-
strated in cells from D299G, but not haplotype, 
carriers [52]. Nonetheless, the TLR4 haplotype 
was associated with the occurrence of infectious 
complications in HIV-1-infected patients – espe-
cially those with a history of low nadir CD4 cell 
counts [53] – and both sepsis and pneumonia in 
patients with acute myeloid leukemia following 
induction chemotherapy [54]. In addition, the 
presence of these TLR4 variants in donors of stem 
cell transplantation has been disclosed as an 
important risk factor for developing invasive 
aspergillosis (IA) in the corresponding patients 
[55], a finding that was confirmed in two indepen-
dent populations [56, 57]. Despite that the fungal 
ligand (or the host- derived molecule released in 
response to fungal infection) for TLR4 remains 
debated, the TLR4 haplotype was reported to 
underlie a delayed T cell and natural killer T cell 
immune reconstitution among stem cell transplant 
recipients [57]. The biological implications of 
these studies are further supported by the previous 
links of TLR4 variants with chronic aspergillosis 
in immunocompetent individuals [58] and fungal 
colonization in stem cell transplant recipients [59].
It is noteworthy that, in addition to TLR4, 
common genetic variation in other TLRs has 
also been proposed to influence the risk of 
infectious diseases. For example, genetic varia-
tion in TLR1 has been found to increase sus-
ceptibility to organ dysfunction and 
Gram-positive sepsis [60] and candidemia [61] 
and, most importantly, to impact the inflamma-
tory response to bacterial lipopeptides [62]. On 
the other hand, a regulatory variant decreasing 
the expression of TLR3 was found to impair the 
recognition of fungal nucleic acids by dendritic 
cells and to compromise the efficient priming 
of protective memory CD8+ T cell responses, 
thereby rendering stem cell transplant recipi-
ents more prone to develop IA [63]. Ultimately, 
the evaluation of regulatory variation impacting 
adaptive immunity might help to enhance the 
discriminatory potential of recent immunodiag-
nostic strategies based on the evaluation of fun-
gal-specific adaptive immune responses [64]. 
Specifically, patients suffering from IA display 
an enhanced in  vitro expansion of IL-10-
producing T cells following antigenic stimula-
tion, and this has been proposed as a potential 
diagnostic approach in hematological patients 
[64]. However, we recently found that a regula-
tory variant in IL-10, and that underlies an 
increased risk of IA, regulated the expression of 
IL-10 and coordinated the activation of proin-
flammatory responses to the fungus [65]. This 
observation implies therefore that diagnostic 
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(and immunotherapeutic) approaches are 
required to consider interindividual variability 
in immune function.
Other significant examples of variants affecting 
TLR signaling and associated with enhanced sus-
ceptibility to infectious disease are those in the 
adaptor Mal (encoded by TIRAP), which is part of 
the TLR2- and TLR4-dependent pathways [6]. 
Polymorphisms in TIRAP, particularly the S180L 
substitution, were initially shown to confer resis-
tance to tuberculosis [66, 67] and septic shock 
[68], although a large meta- analysis failed to con-
firm this [69], ultimately reflecting the difficulties 
faced in ascribing host genetics to enhanced sus-
ceptibility to tuberculosis [13]. A similar case is 
also illustrated by the TLR5 deficiency. TLR5 is a 
receptor for flagellin, the PAMP present in the fla-
gellum of flagellated bacteria [70]. Hawn and col-
leagues described a common polymorphism in 
TLR5 leading to the introduction of an early stop 
codon that was described to abrogate recognition 
of flagellin and leading to increased susceptibility 
to Legionella pneumonia [71]. Of note, this sus-
ceptibility phenotype is generally mild and affects 
the control of only certain flagellated pathogens. 
More recently, TLR5 deficiency was associated 
with increased risk of IA following stem cell trans-
plantation [72], but further studies are warranted to 
identify the mechanism(s) by which TLR5 might 
influence susceptibility to fungal disease. In any 
case, the high and variable frequencies of this 
polymorphism, without forcing a severe primary 
immunodeficiency phenotype, suggest that it has a 
redundant role in host defense [73].
 Genetic Variation in C-Type Lectin 
Receptor Signaling
In addition to TLRs, genetic variation in CLRs 
has been implicated in susceptibility to infectious 
diseases, namely, those caused by fungi (Fig. 6.2). 
Dectin-1 is the major PRR for β-1,3-glucan in the 
fungal cell wall [20], and it also recognizes 
components of Mycobacterium tuberculosis [74]. 
Genetic analysis of a family with recurrent 
vulvovaginal candidiasis and onychomycosis 
resulted in the identification of an early stop 
codon in CLEC7A, the gene encoding dectin-1 
[75]. The truncated protein compromised the 
surface expression of dectin-1  in myeloid cells, 
thereby affecting their ability to bind β-glucan. 
This defect impaired the production of cytokines – 
namely, IL-6, TNF, and especially IL-17 – while 
it did not affect the ability of neutrophils to ingest 
and kill Candida albicans yeasts. This indicates 
that the contribution of dectin-1 deficiency to 
mucosal candidiasis likely relies on a defect in 
the activation of Th17-mediated immunity and 
not on activation of dectin-1 expressed on 
neutrophils.
The clinical phenotype of patients with dec-
tin-1 deficiency is relatively mild and less severe 
than that of patients with classic chronic mucocu-
taneous candidiasis [76]. In fact, about 6 to 8% of 
Europeans are heterozygous for a disabling vari-
ant of the gene, and they do not, however, have an 
apparent immunodeficiency [75]. Yet, heterozy-
gous carriers of the dectin-1 stop codon are more 
prone to develop IA [77, 78] and to be colonized 
with C. albicans [79] when undergoing stem cell 
transplantation. The fact that dectin-1 deficiency 
in both transplant donors and recipients syner-
gizes toward risk of infection highlights the piv-
otal contribution of dectin-1 expression in 
multiple cell types to antifungal immunity. Thus, 
dectin-1 deficiency resembles a genetic polymor-
phism, which under specific circumstances (e.g., 
immunosuppression typical of certain clinical 
settings) is associated with susceptibility to fun-
gal infection and/or colonization. Of note, a com-
mon polymorphism in another CLR, namely, 
MCL (encoded by CLECSF8), was recently asso-
ciated with susceptibility to pulmonary tubercu-
losis, and a non-redundant role for this receptor 
in anti- mycobacterial immunity was proposed 
[80].
Several members of a family with mutations in 
caspase recruitment domain-containing protein 9 
(CARD9), the adaptor molecule that mediates sig-
naling induced by dectin-1 and other CLRs, have 
been found to display increased susceptibility to 
mucocutaneous fungal infections [81]. More 
recently, CARD9 deficiency was identified in 
patients suffering from deep dermatophytosis, a 
severe fungal infection caused by dermatophytes 
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and characterized by extensive dermal and subcu-
taneous tissue invasion and by frequent dissemi-
nation to the lymph nodes and, occasionally, the 
central nervous system. Similar to dectin-1, 
patients with CARD9 mutations display a severe 
defect of IL-17 production [81, 82], a finding fur-
ther supporting the pivotal role of the β-glucan 
recognition and Th17-mediated responses in anti-
fungal immunity. Of note, individuals with inher-
ited defects in B cell CLL/lymphoma 10 (BCL10), 
a protein that binds CARD9 to activate NF-κB 
signaling, displayed normal responses to a variety 
of PAMPs but impaired NF-κB-mediated func-
tions [83]. The fact that susceptibility to infec-
tious diseases was not reported highlights the 
selective role of dectin-1-/CARD9-dependent sig-
naling in the immune response to fungal infec-
tion. Because multiple CLRs signal through 
CARD9, one can hypothesize that the more severe 
phenotypes of CARD9 deficiency are most likely 
due to antifungal immunity mechanisms that are 
independent of dectin-1 [84–86].
 Defects of Soluble Pattern 
Recognition Receptors
Some components of the complement system 
have the capacity to interact with and bind to 
microbial polysaccharides without transducing 
intracellular signals, thereby functioning as solu-
ble PRRs. One such molecule is the circulating 
mannose-binding lectin (MBL), which binds car-
bohydrate structures of microorganisms and acti-
vates the complement system [87]. MBL 
deficiency was initially reported in children with 
recurrent bacterial infections (especially 
Neisseria meningitidis), in addition to viral and 
fungal infections [88]. Subsequent studies 
showed however that polymorphisms in MBL 
drive a strong decrease in the levels of functional 
protein in as much as 8% of individuals in a given 
population, and yet, these do not display any 
obvious clinical consequences [89]. There is 
however evidence that MBL deficiency, although 
not being an outright immunodeficiency, acts as a 
risk factor for infection, especially in conditions 
of immunosuppression. For example, genetically 
determined low serum concentrations of MBL 
were detected among immunocompromised 
patients suffering from IA [90], although the 
causal nature for this association remains 
unknown.
Another important molecule with opsonic 
activity is the long pentraxin 3 (PTX3), which 
has been shown to bind microbial moieties from 
a vast range of pathogens, including bacteria, 
viruses, and fungi [87]. Although no classic 
immunodeficiency phenotype related to PTX3 
has been disclosed to date, common 
polymorphisms have been proposed as risk 
factors for multiple infectious diseases, most 
remarkably, urinary tract infections [91] and IA 
following stem cell transplantation [92]. The 
results from the latter study were confirmed by 
the validation of the association in a large, 
independent study [93]. The PTX3 deficiency 
was found to compromise the alveolar availability 
of the protein and, at a cellular level, its expression 
during the developmental programming of 
neutrophil precursors in the bone marrow, leading 
to defective antifungal effector mechanisms of 
mature cells [92]. Importantly, this association 
was recently replicated in recipients of lung 
transplant [94], highlighting a potential 
applicability of these markers in predicting 
fungal infection across patients with intrinsically 
different predisposing conditions. Alveolar levels 
of PTX3 have been demonstrated to discriminate 
microbiologically confirmed pneumonia in 
mechanically ventilated patients [95]. Given that 
these vary individually according to PTX3 
genotypes [92], we can envisage the quantification 
of PTX3 in bronchoalveolar lavage fluids as a 
complementary surveillance measure in addition 
to the currently available diagnostic approaches. 
Finally, the fact that exogenous administration of 
PTX3 is able to revert the genetic defect in vitro, 
namely, by restoring the ability of neutrophils to 
adequately ingest and kill the fungus [92], further 
highlights the potential of PTX3-based 
immunotherapies to treat (or prevent) fungal 
infection [96].
Other relevant examples of genetic defects in 
soluble PRRs include the identification of a 
deleterious variant in plasminogen – a regulatory 
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molecule with opsonic properties  – as an 
important modulator of susceptibility to IA in 
humans using the genetic mapping analysis of 
survival data of animals subjected to experimental 
infection as discovery strategy [97]. Finally, 
microbial polysaccharides are also recognized by 
β2-integrins such as complement receptor 3 
(CD11b-CD18), which is required for neutrophil 
adhesion to endothelial cells and functions as a 
neutrophil β-glucan receptor [98]. The increased 
susceptibility to recurrent bacterial infections 
displayed by patients with leukocyte adhesion 
deficiency I is mainly due to defective processes 
of leukocyte adhesion.
 Opportunities for Clinical 
Translation of Infectious Disease 
Genetics
Recent studies have clearly implicated genetic 
variation in PRRs and downstream signaling 
pathways in the susceptibility to infectious 
diseases. This is particularly true for several 
immunodeficiency syndromes, in which causal 
effects have been clearly defined and measures 
for patient-tailored management are now in place 
or under evaluation. Nevertheless, considerable 
further work is required in many cases to identify 
the causative alleles, their functional 
consequences, and the biological mechanisms by 
which they influence disease pathogenesis. A 
major challenge is to develop strategies for 
translating insights from the genetic basis of 
common infectious disease into improved patient 
outcomes. This objective has been hampered thus 
far by the size of the genotypic effect, which is 
often not sufficiently discriminatory to inform 
clinical decision-making. To enhance the 
predictive value of the genotypic information, 
future studies are expected to integrate it with 
other host and pathogen factors into combined 
predictive models to prospectively evaluate risk 
of and progression of disease, including treatment 
responses and durations, and adverse events.
It is plausible that the considerable genetic 
variation in PRR signaling may influence 
therapeutic strategies aimed at manipulating 
these pathways. Clinical trials that fail to take 
into account human genetic variation may omit 
relevant consequences on subgroups of 
individuals, such as those with extremes of 
inflammatory signaling. Indeed, such effects may 
partly account for the disappointing outcomes of 
clinical trials of anti-inflammatory agents for the 
treatment of sepsis. Thus, there is a need to 
identify the functional genetic variants controlling 
interindividual variation in PRR signaling and to 
stratify clinical trials of immunomodulatory 
agents by host genotypes.
The use of genetic information to predict risk 
of common infectious disease is unlikely to alter 
clinical practice in the near future, and the prog-
nostic significance of genetic tools for risk assess-
ment remains poor, even in more extensively 
studied, noninfectious disease traits. Clinical 
translation is more likely to result from the char-
acterization of the molecular and cellular path-
ways involved in disease and the identification of 
novel targets for immunomodulatory drugs or 
vaccines, especially in the context of monogenic 
defects. Another interesting example regards the 
identification of the gene defect in PTX3 underly-
ing IA, which raises the possibility to use recom-
binant PTX3 treatment to supplement antifungal 
agents, as demonstrated in animal models of 
infection [99, 100]. Furthermore, the application 
of systems biology to integrate genome-wide 
studies, including genomic, transcriptomic, pro-
teomic, or metabolomic profiles, and their inte-
gration with clinical data may be a particularly 
powerful approach for identifying novel therapeu-
tic targets [101]. Indeed, next-generation sequenc-
ing technologies now provide exciting avenues to 
pin down essential steps in host-pathogen interac-
tions at a level of complexity previously unantici-
pated. Several GWAS exploring susceptibility to 
infection have been completed and provide unbi-
ased insights into the genetic defects contributing 
to the development of disease. In this regard, 
recent functional genomics analyses have allowed 
the identification of new important players con-
trolling susceptibility to candidemia in critical ill 
patients [102, 103]. These efforts are however 
centered on the fairly “static” role of the genetic 
variants. Physiological responses to infection 
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require the coordinated regulation of gene expres-
sion, which may vary markedly between individu-
als and influence phenotypes such as protein 
levels, the immune cell morphology and function, 
and ultimately immunity to infection. Thus, 
genetic analysis of molecular traits such as the 
gene expression represents a powerful approach 
enabling insights into the human genomic land-
scape by generating expression maps useful for 
the functional interpretation of noncoding vari-
ants likely to arise from the ongoing genome-
wide initiatives [104].
 Conclusions and Perspectives
The clinical features of defects in PRRs are gen-
erally credited to an impaired cytokine response 
underlying increased susceptibility to infections 
(e.g., TLR3 and MyD88 deficiencies). Although 
genetic defects in NLRP3 are known to lead to an 
overwhelming release of proinflammatory cyto-
kines, particularly IL-1β, these still remain to be 
associated with infectious diseases. Another criti-
cal point that deserves mention regards the clini-
cal range of manifestations of PRR defects that 
range from severe (e.g., MyD88 and IRAK4 defi-
ciencies) to mild (e.g., MBL, TLR5, and PTX3 
deficiencies). In addition, the fact that several 
defects are associated with infection typically 
during infancy suggests that the maturation of 
proper adaptive immune responses may compen-
sate for the innate immunity shortcomings. The 
field of primary immunodeficiencies has been 
shifting from research on rare familial defects in 
the adaptive immune system to studies of spo-
radic and selective disorders of the innate immu-
nity; the defects in PRRs are an enlightening 
example of this change. By unraveling the func-
tional consequences of these “experiments of 
nature,” it has been possible to confer clinical rel-
evance to immunologic pathways, which until 
now have been studied exclusively in the labora-
tory or using experimental models of infection.
The importance of the studies addressing 
polygenic susceptibility to common infectious 
diseases also deserves to be highlighted. Although 
the overall weight of the immune response is 
driven by adding effects of single genetic factors 
with modest effect sizes and their complex 
interactions with clinical immune dysfunctions, 
approaches based on individual genomics may 
warrant important clinical tools allowing 
discrimination of patients that might benefit from 
enhanced surveillance for infection or alternative 
therapies. By overcoming the limitations related 
to the study design discussed above, these 
approaches are expected to define the pathogenetic 
mechanisms at the basis of common infectious 
diseases and lay the foundations for well- 
designed prospective trials ultimately endorsing 
genetic testing in risk stratification approaches 
for infection, particularly among 
immunocompromised hosts. Perhaps more 
importantly, an improved understanding of the 
multiple pathways directly affected by host 
genetic variation will contribute to innovative 
strategies of immunotherapy. As shown for the 
PTX3 deficiency in stem cell transplant recipients 
[92], targeting cell function (e.g., exogenous 
administration of lacking or deficient factors) 
may prove an interesting approach to be validated 
in the future.
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